Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

Motivation key to post-PCI recovery among women

The results of a Journal of Cardiovascular Nursing study suggest motivation is the key driver of adherence to secondary prevention measures among women who have CHD and have undergone PCI.

Plant-based diets once again linked to lower CVD risk

People who ate the most plant-based foods in a recent Journal of the American Heart Association study were 32% less likely than their counterparts to die from heart disease later down the line.

Thumbnail

Endovascular-first approach boosts amputation-free survival in patients with critical limb ischemia

Patients with critical limb ischemia might be better off if they opt for endovascular-first treatment over an open surgical bypass, a Circulation: Cardiovascular Quality and Outcomes study suggests.

Surgery fails to improve survival in those with severe TR

Surgery doesn’t improve survival in patients with isolated severe tricuspid regurgitation, researchers have found.

Thumbnail

Warm perfusion preserves donor hearts for up to 10 hours

The director of Duke University’s heart transplant program is promoting warm perfusion—a technique that preserves organs more effectively than a traditional cooling box—as a means of expanding the CV donor pool in the U.S.

Thumbnail

Update: FDA acknowledges late mortality signal with paclitaxel devices

The FDA issued an advisory August 7 updating healthcare providers and the public on its stance regarding the long-term safety of paclitaxel-coated and -eluting devices, sharing that its expert panel had indeed identified a late mortality signal associated with the devices.

Thumbnail

‘Heart-on-a-chip’ system replicates human drug response

TARA Biosystems’ “heart-on-a-chip” system successfully replicates human drug responses to CV medications without having to risk cardiotoxicity in human testing, researchers from TARA and GlaxoSmithKline announced August 6.

Thumbnail

NSAIDs heighten CV risk in patients with osteoarthritis

People with osteoarthritis are 23% more likely to develop CVD than their non-arthritic counterparts if they regularly use NSAIDs, according to research published in Arthritis & Rheumatology August 6.